313 related articles for article (PubMed ID: 17438540)
21. The hypothalamus and obesity.
Harrold JA; Halford JC
Recent Pat CNS Drug Discov; 2006 Nov; 1(3):305-14. PubMed ID: 18221212
[TBL] [Abstract][Full Text] [Related]
22. Endocannabinoids and related N-acylethanolamines in the control of appetite and energy metabolism: emergence of new molecular players.
Lambert DM; Muccioli GG
Curr Opin Clin Nutr Metab Care; 2007 Nov; 10(6):735-44. PubMed ID: 18089956
[TBL] [Abstract][Full Text] [Related]
23. Energy balance regulation by endocannabinoids at central and peripheral levels.
Quarta C; Mazza R; Obici S; Pasquali R; Pagotto U
Trends Mol Med; 2011 Sep; 17(9):518-26. PubMed ID: 21816675
[TBL] [Abstract][Full Text] [Related]
24. A critical review of the cannabinoid receptor as a drug target for obesity management.
Akbas F; Gasteyger C; Sjödin A; Astrup A; Larsen TM
Obes Rev; 2009 Jan; 10(1):58-67. PubMed ID: 18721231
[TBL] [Abstract][Full Text] [Related]
25. Anti-obesity drugs and neural circuits of feeding.
Adan RA; Vanderschuren LJ; la Fleur SE
Trends Pharmacol Sci; 2008 Apr; 29(4):208-17. PubMed ID: 18353447
[TBL] [Abstract][Full Text] [Related]
26. Brain neuropeptide Y and CCK and peripheral adipokine receptors: temporal response in obesity induced by palatable diet.
Morris MJ; Chen H; Watts R; Shulkes A; Cameron-Smith D
Int J Obes (Lond); 2008 Feb; 32(2):249-58. PubMed ID: 17768423
[TBL] [Abstract][Full Text] [Related]
27. Obesity therapy: altering the energy intake-and-expenditure balance sheet.
Crowley VE; Yeo GS; O'Rahilly S
Nat Rev Drug Discov; 2002 Apr; 1(4):276-86. PubMed ID: 12120279
[TBL] [Abstract][Full Text] [Related]
28. Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis.
Kunos G; Osei-Hyiaman D
Am J Physiol Gastrointest Liver Physiol; 2008 May; 294(5):G1101-4. PubMed ID: 18292184
[TBL] [Abstract][Full Text] [Related]
29. Role of exercise in the central regulation of energy homeostasis and in the prevention of obesity.
Patterson CM; Levin BE
Neuroendocrinology; 2008; 87(2):65-70. PubMed ID: 17374946
[TBL] [Abstract][Full Text] [Related]
30. PYY transgenic mice are protected against diet-induced and genetic obesity.
Boey D; Lin S; Enriquez RF; Lee NJ; Slack K; Couzens M; Baldock PA; Herzog H; Sainsbury A
Neuropeptides; 2008 Feb; 42(1):19-30. PubMed ID: 18164057
[TBL] [Abstract][Full Text] [Related]
31. Neuropeptide Y and alpha-melanocyte-stimulating hormone: interaction in obesity and possible role in the development of hypertension.
Baltatzi M; Hatzitolios A; Tziomalos K; Iliadis F; Zamboulis Ch
Int J Clin Pract; 2008 Sep; 62(9):1432-40. PubMed ID: 18793378
[TBL] [Abstract][Full Text] [Related]
32. Circumventing central leptin resistance: lessons from central leptin and POMC gene delivery.
Zhang Y; Scarpace PJ
Peptides; 2006 Feb; 27(2):350-64. PubMed ID: 16274846
[TBL] [Abstract][Full Text] [Related]
33. The alphabet of weight control.
Friedman JM
Nature; 1997 Jan; 385(6612):119-20. PubMed ID: 8990109
[No Abstract] [Full Text] [Related]
34. The obesity pipeline: current strategies in the development of anti-obesity drugs.
Cooke D; Bloom S
Nat Rev Drug Discov; 2006 Nov; 5(11):919-31. PubMed ID: 17080028
[TBL] [Abstract][Full Text] [Related]
35. Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine.
Mashiko S; Ishihara A; Iwaasa H; Moriya R; Kitazawa H; Mitobe Y; Ito J; Gomori A; Matsushita H; Takahashi T; MacNeil DJ; Van der Ploeg LH; Fukami T; Kanatani A
Obesity (Silver Spring); 2008 Jul; 16(7):1510-5. PubMed ID: 18421274
[TBL] [Abstract][Full Text] [Related]
36. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
[TBL] [Abstract][Full Text] [Related]
37. Recent insights into body weight control: from physiology to pathology.
Krysiak R; Okopień B; Belowski D; Madej A; Herman ZS
J Pept Sci; 2001 Nov; 7(11):571-8. PubMed ID: 11763361
[TBL] [Abstract][Full Text] [Related]
38. Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status.
Parker E; Van Heek M; Stamford A
Eur J Pharmacol; 2002 Apr; 440(2-3):173-87. PubMed ID: 12007534
[TBL] [Abstract][Full Text] [Related]
39. The role of the endocannabinoid system in the neuroendocrine regulation of energy balance.
Bermudez-Silva FJ; Cardinal P; Cota D
J Psychopharmacol; 2012 Jan; 26(1):114-24. PubMed ID: 21824982
[TBL] [Abstract][Full Text] [Related]
40. Hypothalamic neuronal histamine regulates body weight through the modulation of diurnal feeding rhythm.
Yoshimatsu H
Nutrition; 2008 Sep; 24(9):827-31. PubMed ID: 18725079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
